Kadriu B

Experimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA.

7 papers · 1 preprint · ORCID

ArticleKetamine

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

Jones GH, Gilbert JR, Johnston JN +20

Europe PMC2026
ArticlePsilocybin

Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.

Johnston JN, Jones GH, Peng S +12

Europe PMC2026
PreprintPsilocybin

Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers

Johnston J, Jones G, Peng S +12

Europe PMC2026
ArticleKetamine

Ketamine in neuropsychiatric disorders: an update.

Johnston JN, Kadriu B, Kraus C +2

Europe PMC2024
ArticleKetamine

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.

Johnston JN, Kadriu B, Allen J +3

Europe PMC2023
ArticleKetamine

Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.

Kojic M, Saelens J, Kadriu B +2

Europe PMC2022
ArticleKetamine

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Kadriu B, Greenwald M, Henter ID +4

Europe PMC2021
ArticleKetamine

The influence of ketamine on drug discovery in depression.

Kraus C, Wasserman D, Henter ID +3

Europe PMC2019